These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34562929)

  • 1. Rapid Detection of Gut Microbial Metabolite Trimethylamine N-Oxide for Chronic Kidney Disease Prevention.
    Chang YC; Chu YH; Wang CC; Wang CH; Tain YL; Yang HW
    Biosensors (Basel); 2021 Sep; 11(9):. PubMed ID: 34562929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.
    Gupta N; Buffa JA; Roberts AB; Sangwan N; Skye SM; Li L; Ho KJ; Varga J; DiDonato JA; Tang WHW; Hazen SL
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1239-1255. PubMed ID: 32212854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.
    Tang WH; Wang Z; Kennedy DJ; Wu Y; Buffa JA; Agatisa-Boyle B; Li XS; Levison BS; Hazen SL
    Circ Res; 2015 Jan; 116(3):448-55. PubMed ID: 25599331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facile Fluorescence Monitoring of Gut Microbial Metabolite Trimethylamine
    Yu H; Geng WC; Zheng Z; Gao J; Guo DS; Wang Y
    Theranostics; 2019; 9(16):4624-4632. PubMed ID: 31367245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.
    Zhang W; Miikeda A; Zuckerman J; Jia X; Charugundla S; Zhou Z; Kaczor-Urbanowicz KE; Magyar C; Guo F; Wang Z; Pellegrini M; Hazen SL; Nicholas SB; Lusis AJ; Shih DM
    Sci Rep; 2021 Jan; 11(1):518. PubMed ID: 33436815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota-Dependent Trimethylamine
    Hsu CN; Lu PC; Lo MH; Lin IC; Chang-Chien GP; Lin S; Tain YL
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease.
    Pan S; Zhao D; Duan S; Chen X
    Int Urol Nephrol; 2023 Jul; 55(7):1747-1756. PubMed ID: 36797553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.
    Xu KY; Xia GH; Lu JQ; Chen MX; Zhen X; Wang S; You C; Nie J; Zhou HW; Yin J
    Sci Rep; 2017 May; 7(1):1445. PubMed ID: 28469156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multi-omic Association Study of Trimethylamine N-Oxide.
    Manor O; Zubair N; Conomos MP; Xu X; Rohwer JE; Krafft CE; Lovejoy JC; Magis AT
    Cell Rep; 2018 Jul; 24(4):935-946. PubMed ID: 30044989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gut microbiota and its metabolite trimethylamine-N-oxide (TMAO): a novel regulator in coronary artery disease].
    Li Y; Cui M; Sun J; Wei Q; Liu M; Zhang J; Qi H; Zhao L; Fang H; Chen Z; Lü S
    Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3745-3756. PubMed ID: 34841781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate.
    Pelletier CC; Croyal M; Ene L; Aguesse A; Billon-Crossouard S; Krempf M; Lemoine S; Guebre-Egziabher F; Juillard L; Soulage CO
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31683880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
    Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
    mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide.
    Romano KA; Vivas EI; Amador-Noguez D; Rey FE
    mBio; 2015 Mar; 6(2):e02481. PubMed ID: 25784704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients.
    Zuo K; Liu X; Wang P; Jiao J; Han C; Liu Z; Yin X; Li J; Yang X
    BMC Genomics; 2020 Jul; 21(1):526. PubMed ID: 32731896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.
    El Hage R; Al-Arawe N; Hinterseher I
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide.
    Zhu Y; Li Q; Jiang H
    APMIS; 2020 May; 128(5):353-366. PubMed ID: 32108960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota.
    Hoyles L; Jiménez-Pranteda ML; Chilloux J; Brial F; Myridakis A; Aranias T; Magnan C; Gibson GR; Sanderson JD; Nicholson JK; Gauguier D; McCartney AL; Dumas ME
    Microbiome; 2018 Apr; 6(1):73. PubMed ID: 29678198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.
    Zhen J; Zhou Z; He M; Han HX; Lv EH; Wen PB; Liu X; Wang YT; Cai XC; Tian JQ; Zhang MY; Xiao L; Kang XX
    Front Endocrinol (Lausanne); 2023; 14():1085041. PubMed ID: 36824355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
    Taguchi K; Fukami K; Elias BC; Brooks CR
    Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
    Nanto-Hara F; Kanemitsu Y; Fukuda S; Kikuchi K; Asaji K; Saigusa D; Iwasaki T; Ho HJ; Mishima E; Suzuki T; Suzuki C; Tsukimi T; Matsuhashi T; Oikawa Y; Akiyama Y; Kure S; Owada Y; Tomioka Y; Soga T; Ito S; Abe T
    Nephrol Dial Transplant; 2020 Feb; 35(2):250-264. PubMed ID: 31411705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.